• Case-Based Roundtable
  • General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

News

Article

Enhancing Patient Care Through Innovation

Key Takeaways

  • Omar Noor, MD, FAAD, uses a buy-and-bill model to optimize patient access to biologic therapies, enhancing care and operational efficiency.
  • Direct medication purchase and reimbursement have expanded services, benefiting Medicare patients with secondary insurance coverage.
SHOW MORE

Noor noted patients benefit from in-house injection services, avoiding the inconvenience of traveling to off-site centers.

During a Dermatology Times custom video series titled, “Understanding Buy and Bill for Medical Dermatology,” Omar Noor, MD, FAAD,a board-certified dermatologist based in New York City and New Jersey, explored how the process has assisted in optimizing patient access to biologic therapies. As an attending physician at Penn Medicine and the official dermatologist for the Brooklyn Nets, Noor’s innovative approach reflects a commitment to both patient care and operational efficiency.

When considering a biologic for a patient, Noor said his primary focus is ensuring access. If a specific medication is determined to be the best option, but access can only be achieved by purchasing the medication directly and obtaining reimbursement afterward, his practice proceeds with that route. This strategy has expanded the range of services offered, particularly benefiting Medicare patients with secondary insurance coverage.

Initially, Noor said his practice relied heavily on tildrakizumab, a biologic commonly used in buy-and-bill models. However, insurance requirements often mandated that injections occur at off-site infusion centers, which placed a significant burden on patients who had to travel to these locations. Recognizing this challenge, Noor brought these services in-house, simplifying care and improving patient satisfaction. Patients now receive their injections at the practice, which he says they’ve greatly appreciated. This shift has also allowed for closer monitoring of adherence, enabling the team to address missed or late injections promptly and improving the consistency and efficacy of treatments.

Beyond enhancing patient care, Noor’s model offers operational advantages. By leveraging credit card programs for biologic purchases, his practice benefits from cash-back rewards or points, further enhancing margins. While navigating the nuances of billing and purchasing requires diligence, these strategies have proven effective in making biologic therapies more accessible and manageable for both patients and providers.

Noor’s approach underscores the importance of innovation in clinic practices, highlighting how thoughtful integration of biologic purchasing can improve outcomes and streamline operations.

© 2025 MJH Life Sciences

All rights reserved.